Search Results 411-420 of 16654 for pharmacogenetics
The purpose of this study is to evaluate the feasibility of molecular characterization based on tumor mutational burden (TMB) for participant stratification ...
ROCHESTER, Minn. — For many people living with cancer, symptoms such as pain, anxiety or insomnia can quickly spiral into an emergency room visit. Such[...] ...
PHOENIX — Current genetic screening guidelines fail to identify most people with an inherited condition known as familial hypercholesterolemia that can ...
Biostatisticians bring a unique perspective and skill set to every step of medical research. Last year, at Mayo Clinic they supported about 5,000 studies ...
Individualized medicine, also known as personalized medicine or precision medicine, is tailoring diagnosis and treatment to each patient to optimize care.
ROCHESTER, Minn. — At Mayo Clinic, cardiologists Peter Noseworthy, M.D., and John Giudicessi, M.D., Ph.D., are uncovering the earliest signs of a genetic heart ...
A PSP genome-wide association study (GWAS) identified six novel risk loci, in addition to the established H1 haplotype on chromosome 17 at the tau gene (MAPT) ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with estrogen receptor ...
Coagulation factor IX (recombinant), glycoPEGylated injection is used to control bleeding episodes and prevent bleeding during surgery in patients with ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift can go 3X as far to shape the future of cancer care.